Acoustic hydrogen delivery to treat PANoptosis induced by myocardial ischemia/reperfusion injury in rats.
Shu-Hui Wang, Chen-Hui Li, Zi-Jun Wei, Cai-Yun Tang, Yong Wang, Fei Yan, Qian Li · Biomaterials advances · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In a rat model of MIR injury, intravenous injection of H₂-MBs followed by ultrasound-targeted microbubble destruction (UTMD) significantly improved cardiac function (ejection fraction and fractional shortening), reduced infarct size, and attenuated tissue damage. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in rats. In a rat model of MIR injury, intravenous injection of H₂-MBs followed by ultrasound-targeted microbubble destruction (UTMD) significantly improved cardiac function (ejection fraction and fractional shortening), reduced infarct size, and attenuated tissue damage.
What the Researchers Studied
The researchers studied rats. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Although molecular hydrogen (H₂) possesses therapeutic potential, its clinical translation is hindered by poor solubility and the lack of targeted delivery and real-time monitoring capabilities. The fabricated H₂-MBs exhibited uniform spherical morphology (0.92 ± 0.03 μm), high concentration ((1.14 ± 0.07) × 1010 bubbles/mL), and efficient H₂ encapsulation, enabling real-time contrast-enhanced ultrasound imaging. In a rat model of MIR injury, intravenous injection of H₂-MBs followed by ultrasound-targeted microbubble destruction (UTMD) significantly improved cardiac function (ejection fraction and fractional shortening), reduced infarct size, and attenuated tissue damage.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was rats. The study used a preclinical animal experiment.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.